Related references
Note: Only part of the references are listed.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
Daniel A. Pollyea et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Gautam Borthakur et al.
BLOOD CANCER JOURNAL (2021)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
The clinical mutatome of core binding factor leukemia
Sabrina Opatz et al.
LEUKEMIA (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis
Nicholas J. Short et al.
JAMA ONCOLOGY (2020)
Response kinetics and factors predicting survival in core-binding factor leukemia
Prajwal Boddu et al.
LEUKEMIA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Metronomic chemotherapy and nanocarrier platforms
Amr S. Abu Lila et al.
CANCER LETTERS (2017)
Metronomic chemotherapy for advanced breast cancer patients
Marina Elena Cazzaniga et al.
CANCER LETTERS (2017)
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia
Juan Ouyang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for prime time?
David Grimwade et al.
BLOOD (2014)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy
Hong-Hu Zhu et al.
LEUKEMIA & LYMPHOMA (2013)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R. Loken et al.
BLOOD (2012)
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
Shuichi Miyawaki et al.
BLOOD (2011)
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Y Shaked et al.
BLOOD (2005)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Core-binding factors in haematopoiesis and leukaemia
NA Speck et al.
NATURE REVIEWS CANCER (2002)
Share Paper
